期刊
CANCER TREATMENT REVIEWS
卷 66, 期 -, 页码 82-94出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2018.04.006
关键词
Non-small cell lung cancer (NSCLC); BRAF mutations; Mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway; Vemurafenib; Dabrafenib; Trametinib
类别
资金
- AstraZeneca
- Pfizer
- Eli-Lilly
- BMS
- Novartis
- Roche
- MSD
- Boehringer Ingelheim
- Otsuka
- Pierre Fabre
Molecular characterization of non-small cell lung cancer (NSCLC) marked an historical turning point for the treatment of lung tumors harboring kinase alterations suitable for specific targeted drugs inhibition, translating into major clinical improvements. Besides EGFR, ALK and ROS1, BRAF represents a novel therapeutic target for the treatment of advanced NSCLC. BRAF mutations, found in 1.5-3.5% of NSCLC, are responsible of the constitutive activation of mitogen activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway. Clinical trials evaluating the efficacy of the BRAF inhibitor dabrafenib in combination with the downstream MEK inhibitor trametinib in metastatic BRAF(V600E)-mutated NSCLC guaranteed FDA and EMA rapid approval of the combination regimen in this clinical setting. In line with the striking results observed in metastatic melanoma harboring the same molecular alteration, BRAF and MEK inhibition should be considered a new standard of care in this molecular subtype of NSCLC. In the present review, we propose an overview of the available evidence about BRAF in NSCLC mutations (V600E and non-V600E), from biological significance to emerging clinical implications of BRAF mutations detection. Focusing on the current strategies to act against the mutated kinase, we moreover approach additional strategies to overcome treatment resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据